Sygnature Discovery expands into early CMC development Kumar Jeetendra | June 16, 2021 NOTTINGHAM, UK – 16 June, 2021 –– Leading Drug Discovery Contract Research Organisation Sygnature Discovery has announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. Located at its headquarters in Nottingham, UK, the new service line will expand on the company’s offerings to customers by bridging into formal preclinical drug development and paving …
